Fenwick Represents OrsoBio in $60 Million Series A Financing

Fenwick represented OrsoBio, a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, in its $60 million Series A financing. The round was co-led by Longitude Capital and Enavate Sciences, with participation from Samsara BioCapital, NuevaBio and Eli Lilly and Company.

OrsoBio will use the funds to support the advancement of OrsoBio’s obesity-focused portfolio. More information can be obtained from the company’s announcement.

The Fenwick transaction team was led by corporate partner Bill Bromfield and included associates Leeza Soulina and Jing Liu.